CYTOTRON

The Cytotron® is a non-invasive whole body therapeutic device that is a breakthrough in tissue engineering.

The Cytotron® is a stand-alone device based on Rotational Field Quantum Magnetic Resonance (RFQMR) platform technology which enables whole body therapeutics called Quantum Magnetic Resonance Therapy (QMRT). QMRT is the Cytotron® device-mediated, innovative therapeutic modality for tissue Degeneration (for Cancer) and Regeneration (for human degenerative disease indications), currently in the clinical stage of development in the US. The Cytotron® operates at the safe end of the Electromagnetic Spectrum, and therapeutic signals are lower than microwave and cellphone frequencies.

Cytotron Facts

• The Cytotron® has been clinically validated since 2004

• European Union CE Mark-Certified for use in Musculoskeletal Disorders and Cancer (since 2012)

• Awarded USA, European, and Chinese Patents

  • US Patent - US9162076B2

  • European Patent - EP1753508B1

  • Chinese Patent - CN1960779B

• Off-shore clinical validation concluded in both adult and pediatric solid tumors in Mexico City, Mexico

  • Compassionate study in all Adult solid tumors (Brain, Breast, Colon, Prostate and Lung Cancers) at the Govt. Social Security Administration Hospital

  • Compassionate study in Pediatric Brain tumors* at the National Children’s Hospital in Mexico City. *The Pediatric brain tumor trial protocol was registered with the National Institutes of Health (LINK)

• Patient & User friendly with high patient compliance in all age groups

• Cost effective with minimal infrastructure and maintenance costs

• Markedly reduced and affordable pricing compared to conventional or newer drugs/therapies

• More than 30 commercial and private installations world-wide

The Cytotron® technology platform is very unique in that tissue regeneration or degeneration can happen by triggering inherent stem cell responses. Wound healing and tissue regeneration protocols do not require the use of an external source of stem cells, at the high costs associated with nascent stem cell therapies.

Tissue Degeneration - Cancer

On October 24th 2019, the Cytotron was granted Breakthrough Device Designation by the U.S. FDA for Breast, Liver, and Pancreatic Cancers. (LINK) Additional solid tumor indications of use and other life-limiting indications are being pursued in parallel.

The Cytotron® device delivers rotating, target-specific, modulated, safe Radio Frequencies in the presence of a pulsed, integrated, instantaneous magnetic field. The presumed modulation of the transmembrane potential of tumor cells and downstream cellular signaling by RF for tissue degeneration in cancer underlies Rotational Field Quantum Magnetic Resonance platform technology. Whole body MRI for tissue proton density determinations is used to compute individualized dosimetry to target solitary or multiple regions of interest in the whole body, simultaneously. Exposure to QMRT is for 1 hour daily for 28 consecutive days. Quality of Life assessments, overall survival and tumor stability endpoints have shown remarkable improvement over standard of care related treatment outcomes (see publication in a peer-reviewed journal in Resources).

Tissue Regeneration - Osteoarthritis & other Indications

Osteoarthritis (OA) is a pathology which causes severe and long-term pain along with physical disability.

• It is characterized by a progressive destruction of articular cartilage accompanied by subchondral bone remodeling, osteophyte formation and synovial membrane inflammation

• This disorder is classified as non-inflammatory arthritis and it is the most common form of arthritis affecting people of all ages, including children

• So far, no pharmacological treatment exists targeting the mechanisms of OA

• The underlying etiopathology of OA modulated by fast radio bursts (FRB) is detailed in a recent publication (see Resources)

• The commonly used treatments principally target symptoms of OA but doesn’t prevent its progression

• There is an unmet medical need for protecting cartilage degradation, decreasing joint pain and eventually healing joint inflammation as OA progresses from an acute to a chronic state

QMRT is able to re-grow cartilage in the joints, significantly reducing pain, increasing mobility, range of motion and functionality based on International Knee Society Scores and outcome reporting, post QMRT.

Clinically validated Indications of USE with the Cytotron® and QMRT are;

• Musculo-skeletal (Osteoarthritis of all joints)

• Musculo-skeletal degeneration (Spinal Dysplasia / Disc Prolapse or Herniated Disc Repair)

• Wound & Burn healing (see Resources for image of post-traumatic multi-organ regeneration of one digit of the little toe- manuscript under preparation).

• Trauma / Surgery - induced muscular weakness in extremities

Other Areas of Study

Pilot studies are also being conducted using non-invasive tissue engineering in multiple indications, at Shreis Scalene Sciences’ Technology Partner & Cytotron Inventor’s Scalene Center for Advanced Research and Development (S-CARD) in Bengaluru, India including Kidney failure, insulin-dependent diabetes and degenerative Lung Disease etc.

Clinical Trials

For CYTOTRON® and CELLFORN®, clinical trials will be managed by Shreis Scalene Clinicals Inc. More…

Please visit the Resource tab for more detailed information about Cytotron, including; journal articles, brochures, patents, and media